{"gene":"SMYD2","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":2006,"finding":"SMYD2 methylates p53 at lysine 370 (monomethylation), repressing p53-mediated transcriptional activity. Set9-mediated methylation of p53 K372 inhibits SMYD2-mediated K370 methylation in part by blocking the p53-SMYD2 interaction, establishing cross-talk between activating and repressing lysine methylation marks on p53.","method":"In vitro methyltransferase assay, siRNA knockdown, co-immunoprecipitation, apoptosis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — in vitro methyltransferase assay plus interaction studies, replicated across multiple labs subsequently","pmids":["17108971"],"is_preprint":false},{"year":2006,"finding":"SMYD2 mediates histone H3K36 dimethylation via its SET domain, represses transcription from a reporter, and associates specifically with the Sin3A histone deacetylase complex. Overexpressed SMYD2 localizes to both cytoplasm and nucleus.","method":"Histone methyltransferase assay, co-immunoprecipitation with Sin3A complex, reporter gene assay, subcellular localization by immunofluorescence","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2/3 / Moderate — in vitro HMT assay and Co-IP, single lab, multiple orthogonal methods","pmids":["16805913"],"is_preprint":false},{"year":2007,"finding":"SMYD2 interacts with HSP90α independently of its SET and MYND domains, and this interaction enhances SMYD2 histone methyltransferase activity and specificity for H3K4 in vitro. SMYD2 interacts with EBP41L3 through the MYND domain and with p53 through the SET domain.","method":"Immunoprecipitation coupled to mass spectrometry, co-immunoprecipitation, in vitro methyltransferase assay, chromatin IP","journal":"Molecular & cellular proteomics : MCP","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and domain-mapping experiments, single lab, multiple orthogonal methods","pmids":["18065756"],"is_preprint":false},{"year":2010,"finding":"SMYD2 methylates RB at lysine 860 in vitro and in cells; this monomethylation provides a direct binding site for the methyl-binding domain of the transcriptional repressor L3MBTL1. Methylation is regulated during cell cycle progression, differentiation, and in response to DNA damage.","method":"In vitro methyltransferase assay, mass spectrometry, pulldown with L3MBTL1 methyl-binding domain, cell-cycle analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro assay, MS-confirmed site, biochemical reader recruitment, independently confirmed by subsequent studies","pmids":["20870719"],"is_preprint":false},{"year":2011,"finding":"Crystal structures of SMYD2 in complex with p53 substrate and product peptides, and with the inhibitor AZ505, reveal that the substrate (p53 peptide) binds in the peptide-binding groove between the SET domain and C-terminal domain (CTD), and that AZ505 is a substrate-competitive inhibitor occupying this same groove.","method":"X-ray crystallography, high-throughput chemical screen, biochemical inhibition assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with bound substrate peptides and inhibitor, replicated by multiple subsequent structural studies","pmids":["21782458"],"is_preprint":false},{"year":2011,"finding":"Crystal structures of SMYD2 bound to cofactor product S-adenosylhomocysteine or inhibitor sinefungin reveal that the CTD stabilizes an autoinhibited conformation and restricts access to the catalytic site; sinefungin binding causes outward bending of the first two CTD helices, demonstrating conformational flexibility of the TPR-like CTD.","method":"X-ray crystallography","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures with two different ligands revealing conformational change, single lab","pmids":["21738746"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of full-length SMYD2 in complex with SAM cofactor and p53 peptide shows the substrate binds in a U-shaped conformation in a deep pocket between the SET domain and CTD. The tetratricopeptide repeat (TPR) motif of the CTD and an EDEE motif are critical for p53 substrate binding specificity; deletion of CTD or mutation of EDEE impairs SMYD2 methylation of p53.","method":"X-ray crystallography, domain deletion and site-directed mutagenesis, in vitro methyltransferase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis with functional validation in one study","pmids":["21880715"],"is_preprint":false},{"year":2011,"finding":"SMYD2 methylates HSP90 at K209 and K615 (nucleotide-binding and dimerization domains, respectively); each methylation site shows unique reactivity to HSP90 co-chaperones, pH, and demethylation by LSD1.","method":"Proteomic interactome mapping, Co-IP, in vitro methyltransferase assay, mass spectrometry","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-confirmed methylation sites and biochemical characterization, single lab","pmids":["22028380"],"is_preprint":false},{"year":2012,"finding":"SMYD2 methylates the cytoplasmic chaperone HSP90 in multiple cell types; in muscle, HSP90 methylation promotes formation of a Smyd2–Hsp90–titin (N2A domain) complex. Smyd2 deficiency causes loss of Hsp90 methylation, impaired titin stability, and altered skeletal muscle function.","method":"In vitro methyltransferase assay, co-immunoprecipitation, zebrafish morpholino knockdown, muscle function assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — in vitro assay, Co-IP complex, in vivo loss-of-function with functional phenotype","pmids":["22241783"],"is_preprint":false},{"year":2012,"finding":"SMYD2 methylates RB1 at lysine 810 (identified by LC-MS/MS); this methylation enhances Ser807/811 phosphorylation of RB1 both in vitro and in vivo, accelerates E2F transcriptional activity, and promotes G1/S cell cycle progression.","method":"In vitro methyltransferase assay, LC-MS/MS, in vivo methylation/phosphorylation assays, E2F reporter, cell cycle analysis, siRNA knockdown","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — MS-confirmed site, in vitro and in vivo functional validation, crosstalk with phosphorylation demonstrated","pmids":["22787429"],"is_preprint":false},{"year":2012,"finding":"Smyd2 associates with the sarcomeric I-band at the titin N2A domain in cardiomyocytes; binding to N2A occurs in vitro and in yeast via N-terminal and extreme C-terminal regions of Smyd2. Smyd2 knockdown in zebrafish strongly impairs cardiac performance.","method":"In vitro binding assay, yeast two-hybrid, zebrafish morpholino knockdown, cardiac function measurement","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding, yeast two-hybrid domain mapping, in vivo cardiac phenotype in zebrafish","pmids":["23047121"],"is_preprint":false},{"year":2013,"finding":"SMYD2 directly methylates ERα at lysine 266 (K266) in vitro and in MCF7 cells; this methylation attenuates chromatin recruitment of ERα and represses ERα target gene activation under estrogen-depleted conditions. Upon estrogen stimulation, K266 methylation is diminished, enabling p300/CBP to acetylate K266 and promote ERα transactivation, establishing cross-talk between SMYD2-mediated methylation and acetylation.","method":"In vitro methyltransferase assay, chromatin immunoprecipitation, gene expression analysis, siRNA knockdown","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — in vitro assay, ChIP, functional gene expression data, crosstalk mechanism defined","pmids":["24101509"],"is_preprint":false},{"year":2014,"finding":"Crystal structure of SMYD2 in complex with an ERα K266-containing peptide shows ERα binds in a U-shaped conformation with binding specificity determined mainly by residues C-terminal to the target lysine. Comparison with SMYD2–p53 structure reveals distinct substrate binding modes underlying SMYD2's broad substrate specificity.","method":"X-ray crystallography","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with structural comparison, single lab","pmids":["24594358"],"is_preprint":false},{"year":2014,"finding":"SMYD2 monomethylates PARP1 at lysine 528 (confirmed by LC-MS/MS and Edman degradation); methylated PARP1 shows enhanced poly(ADP-ribose) formation after oxidative stress, positively regulating PARP1 poly(ADP-ribosyl)ation activity.","method":"In vitro methyltransferase assay, LC-MS/MS, Edman degradation, PAR formation assay","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 1 / Moderate — MS-confirmed methylation site, functional enzymatic activity assay, single lab","pmids":["24726141"],"is_preprint":false},{"year":2014,"finding":"SMYD2 methylates HSP90AB1 at lysines 531 and 574; these methylation sites are important for HSP90AB1 dimerization and chaperone complex formation. HSP90AB1 interacts with SMYD2 through the C-terminal region of HSP90AB1 and the SET domain of SMYD2.","method":"In vitro and in vivo methyltransferase assays, mass spectrometry, co-immunoprecipitation, proliferation assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 1/2 / Moderate — MS-confirmed sites, biochemical domain mapping, single lab","pmids":["24880080"],"is_preprint":false},{"year":2015,"finding":"SMYD2 methylates PTEN at lysine 313 in vitro and in vivo; K313 methylation negatively regulates PTEN tumor suppressor activity, attenuates PTEN S380 phosphorylation, and results in AKT pathway activation. SMYD2 knockdown reduces AKT phosphorylation in breast cancer cells.","method":"In vitro methyltransferase assay, MS confirmation, site-directed mutagenesis (K313A), phosphorylation assays, siRNA knockdown","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 1/2 / Moderate — in vitro assay, mutagenesis, in vivo functional validation, single lab","pmids":["25925379"],"is_preprint":false},{"year":2015,"finding":"SMYD2 is primarily cytoplasmic by subcellular fractionation; inhibition with LLY-507 does not significantly affect global histone methylation levels (by MS-based proteomics), suggesting SMYD2 targets non-histone substrates or a small subset of histones at specific loci.","method":"Subcellular fractionation, SILAC-based mass spectrometry, selective inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation and quantitative proteomics, single lab, two orthogonal methods","pmids":["25825497"],"is_preprint":false},{"year":2015,"finding":"Smyd2 specifically facilitates H3K36 dimethylation at TNF and IL6 gene promoters in macrophages, suppressing their transcription and inhibiting NF-κB and ERK signaling, resulting in reduced macrophage activation and M1 polarization.","method":"ChIP assay, siRNA knockdown, cytokine measurement, signaling pathway analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming H3K36me2 at specific promoters, functional cytokine output, single lab","pmids":["25583990"],"is_preprint":false},{"year":2016,"finding":"SILAC-based proteomics identified 35 cellular monomethyl-lysine (Kme1) sites potently down-regulated by both shRNA knockdown and the selective SMYD2 inhibitor LLY-507 in ESCC cells, including BTF3-K2, PDAP1-K126, and numerous sites in AHNAK and AHNAK2, revealing diverse SMYD2 substrate specificity in cells.","method":"SILAC, immunoaffinity enrichment of Kme1 peptides, mass spectrometry, shRNA knockdown, small molecule inhibitor","journal":"Molecular & cellular proteomics : MCP","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — quantitative proteomics with orthogonal genetic and chemical validation, large-scale rigorous study","pmids":["26750096"],"is_preprint":false},{"year":2016,"finding":"SMYD2 was identified as essential for robust BMP- (but not TGFβ-) induced target gene expression; SMYD2 methylates the kinase domain of BMPR2 (BMP type II receptor), promoting BMPR2 kinase activity and downstream SMAD1/5 phosphorylation and nuclear localization.","method":"RNAi screen, CRISPR/Cas9 knockout, shRNA knockdown, in vitro methyltransferase assay, SMAD1/5 phosphorylation assays, nuclear localization assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methyltransferase assay of BMPR2, genetic validation by KD/KO, functional signaling readout, single lab","pmids":["28588028"],"is_preprint":false},{"year":2017,"finding":"SMYD2 associates with latent HIV-1 promoter chromatin enriched in H4K20me1; SMYD2 knockdown or pharmacological inhibition reactivates latent HIV-1 in T cells. L3MBTL1, a chromatin-compacting H4K20me1 reader, is recruited to the latent HIV-1 promoter in a SMYD2-dependent manner.","method":"RNAi screen, pharmacological inhibition, chromatin immunoprecipitation, HIV latency reactivation assay","journal":"Cell host & microbe","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP showing SMYD2 and H4K20me1 at HIV promoter, L3MBTL1 recruitment, functional reactivation assay, single lab","pmids":["28494238"],"is_preprint":false},{"year":2017,"finding":"SMYD2 methylates β-catenin at lysine 133; K133 methylation is critical for β-catenin nuclear translocation and interaction with FOXM1. K133A substitution almost completely abolishes nuclear localization. SMYD2 knockdown reduces nuclear β-catenin and downstream Wnt target gene expression.","method":"In vitro methyltransferase assay, site-directed mutagenesis (K133A), nuclear fractionation, co-immunoprecipitation, gene expression analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus localization studies and CoIP, single lab","pmids":["28915556"],"is_preprint":false},{"year":2017,"finding":"SMYD2 methylates ALK at lysines 1451, 1455, and 1610; K1610A substitution reduces AKT phosphorylation and cell growth, and SMYD2 knockdown attenuates EML4-ALK phosphorylation in NSCLC cells.","method":"In vitro methyltransferase assay, site-directed mutagenesis, phosphorylation assays, siRNA knockdown, cell proliferation assay","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro assay, mutagenesis with functional readout, single lab","pmids":["28370702"],"is_preprint":false},{"year":2017,"finding":"SMYD2 carries out its pro-cystic function via methylation and activation of STAT3 and the p65 subunit of NF-κB, leading to increased renal epithelial cell proliferation and survival. Two positive feedback loops were identified: SMYD2/IL-6/STAT3/SMYD2 and SMYD2/TNF-α/NF-κB/SMYD2.","method":"In vivo Pkd1 knockout mouse models, pharmacological inhibition with AZ505, in vitro methyltransferase assay, signaling pathway analysis","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic and pharmacological models, biochemical substrate methylation, single lab","pmids":["28604386"],"is_preprint":false},{"year":2018,"finding":"SMYD2 glutathionylation at Cys13 (identified by clickable glutathione approach) causes loss of its interaction with Hsp90 and the titin N2A domain. Upon dissociation, titin/N2A is degraded by activated MMP-2, establishing a mechanism by which ROS-induced SMYD2 glutathionylation leads to sarcomere destabilization.","method":"Clickable glutathione labeling, biochemical Co-IP, proteolysis assays with MMP-2 and calpain 1","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel chemical biology method for glutathionylation site, biochemical functional consequence, single lab","pmids":["30337525"],"is_preprint":false},{"year":2018,"finding":"HSP90 and co-chaperone P23 contain a (M/I/L/V)PXL motif at their C-termini that mediates interaction with SMYD2 independently of the HSP90 EEVD motif. In a reconstituted bacterial system, SMYD2 binding to HSP90/P23 considerably increases methylation of ERα K266, linking chaperone complex formation to ERα methylation efficiency.","method":"Alpha proximity assay, synthetic peptide competition, bacterial reconstitution system, in vitro methyltransferase assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1/2 / Moderate — reconstituted system with defined motif, functional methylation assay, single lab","pmids":["30190324"],"is_preprint":false},{"year":2019,"finding":"SMYD2 directly methylates EZH2 at lysine 307 (K307), enhancing EZH2 protein stability; LSD1 can reverse this methylation. SMYD2-mediated EZH2 K307 methylation promotes breast cancer cell proliferation, EMT, and invasion through stabilized EZH2 function.","method":"In vitro methyltransferase assay, mass spectrometry, co-immunoprecipitation, protein stability assay, siRNA knockdown","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methylation, MS confirmation, LSD1 demethylation, single lab","pmids":["31693890"],"is_preprint":false},{"year":2019,"finding":"Peptide array profiling of SMYD2 substrate specificity revealed preference for leucine (or phenylalanine) at the -1 position and disfavor of acidic residues at +1 to +3 positions; using this motif, 32 novel peptide substrates and 14 novel protein substrates were identified by in vitro methyltransferase assays.","method":"Peptide arrays, in vitro methyltransferase assays","journal":"Chembiochem","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — systematic peptide array plus protein-level validation, single lab","pmids":["31612581"],"is_preprint":false},{"year":2019,"finding":"Six novel SMYD2 substrates (MAPT, CCAR2, EEF2, NCOA3, STUB1, UTP14A) were confirmed by immunoprecipitation in cells; methylation was abrogated by the selective SMYD2 inhibitor BAY-598, confirming dependence on SMYD2 catalytic activity.","method":"Bioinformatic prediction, co-immunoprecipitation, selective inhibitor treatment","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cell-based IP with chemical probe validation across multiple substrates, single lab","pmids":["27163177"],"is_preprint":false},{"year":2020,"finding":"CDK4/6 directly phosphorylates SMYD2, positively regulating its enzymatic activity; SMYD2 in turn positively regulates CDK4/6 expression. SMYD2 functions as an α-tubulin methyltransferase, connecting CDK4/6-SMYD2 signaling to microtubule dynamics and ciliogenesis.","method":"Kinase assay, in vitro methyltransferase assay, CDK4/6 inhibitor treatment, SMYD2 depletion, cilia assembly assay","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase and methyltransferase assays, genetic depletion with functional cilia phenotype, single lab","pmids":["33127671"],"is_preprint":false},{"year":2021,"finding":"SMYD2 methylates TRAF2 in the cytoplasm; SMYD2-mediated TRAF2 methylation stabilizes TRAF2 against proteolysis and enhances NF-κB signaling activity. LSD1 demethylates TRAF2 to counteract this modification.","method":"Mass spectrometry, pulldown, co-immunoprecipitation, methyltransferase assay, ubiquitination assay, luciferase reporter, in vivo inflammation models","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-confirmed methylation, multiple biochemical assays, single lab","pmids":["34841684"],"is_preprint":false},{"year":2022,"finding":"SMYD2 methylates Ku70 at lysines 74, 516, and 539 in response to DNA damage, leading to increased recruitment of the Ku70/Ku80/DNA-PKcs complex to DNA damage sites and promoting NHEJ repair. SMYD2 inhibition causes persistent DNA damage, cytosolic DNA accumulation, and activation of the cGAS-STING pathway with increased CD8+ T cell infiltration.","method":"Co-IP, in vitro methyltransferase assay (Ku70), DNA damage response assays, cGAS-STING pathway analysis, immune cell profiling","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-specific methylation and NHEJ complex recruitment demonstrated, immune pathway functional consequence, single lab","pmids":["37315132"],"is_preprint":false},{"year":2022,"finding":"SMYD2 methylates RIPK1 and inhibits RIPK1 phosphorylation, thereby restricting TNF-induced apoptosis and necroptosis in colon tumor cells and supporting tumor growth.","method":"SMYD2 deficiency experiments, RIPK1 phosphorylation assays, apoptosis/necroptosis assays, tumor growth models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined signaling phenotype (RIPK1 phosphorylation), single lab","pmids":["35022391"],"is_preprint":false},{"year":2022,"finding":"STUB1 (an E3 ubiquitin ligase) mediates ubiquitin-dependent degradation of SMYD2 in response to cisplatin treatment; STUB1 knockdown reverses SMYD2 degradation and impairs cisplatin efficacy in glioma cells.","method":"UbiBrowser prediction, co-IP, siRNA knockdown, protein stability assay","journal":"Journal of molecular neuroscience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and knockdown experiment, no direct ubiquitination reconstitution shown in abstract","pmids":["35939202"],"is_preprint":false},{"year":2022,"finding":"SMYD2 methylates c-Myc to increase its protein stability by reducing K48-linked polyubiquitination and proteasomal degradation; stabilized c-Myc upregulates GLS1, promoting glutamine metabolism in hepatocellular carcinoma.","method":"Co-IP, ubiquitination assay, in vitro methyltransferase assay, siRNA knockdown, gene expression analysis","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methyltransferase assay, ubiquitination changes, metabolic functional readout, single lab","pmids":["36611819"],"is_preprint":false},{"year":2022,"finding":"SMYD2 regulates VSMC contractile phenotype by promoting expression and transactivation of myocardin; myocardin directly interacts with SMYD2 and facilitates SMYD2 recruitment to CArG regions of SMC contractile gene promoters, where SMYD2-mediated H3K4 methylation creates an open chromatin state. SMYD2 ablation in VSMCs exacerbates neointima formation.","method":"SMC-specific SMYD2 knockout mice, genome-wide transcriptome analysis, ChIP, Co-IP, carotid artery injury model","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — SMC-specific KO in vivo plus ChIP and CoIP defining mechanism, single lab","pmids":["37615725"],"is_preprint":false},{"year":2023,"finding":"SMYD2 directly methylates SMAD3, and epigenetic regulation by SMYD2 upregulates SMAD3 expression, thereby promoting lung cancer metastasis. SMYD2 knockdown reduces SMAD3 levels and cell migration/invasion.","method":"siRNA knockdown, in vitro EMT system, ChIP, in vivo metastasis models","journal":"Experimental & molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and KD showing transcriptional regulation; direct methylation of SMAD3 not definitively established in abstract","pmids":["37121971"],"is_preprint":false},{"year":2023,"finding":"SMYD2 promotes HDAC3 expression via H3K36 trimethylation at the HDAC3 promoter; HDAC3 then directly interacts with and deacetylates SRF, enhancing SRF transcriptional activity and VSMC proliferation. SMYD2 knockdown represses SRF target genes and inhibits neointima formation.","method":"Transcriptome sequencing, ChIP, Co-IP, Smyd2-vTg mouse, carotid injury model, HDAC3 inhibitor studies","journal":"Acta pharmaceutica sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming H3K36me3 at HDAC3 promoter, Co-IP of HDAC3-SRF, in vivo model, single lab","pmids":["38322347"],"is_preprint":false},{"year":2024,"finding":"SMYD2 methylates KMT2D at K1330, adjacent to the PI3K-regulated S1331 phosphorylation site; K1330 methylation promotes KMT2D chromatin binding. SMYD2 loss attenuates alpelisib-induced KMT2D binding and ERα-dependent transcription, and sensitizes ER+ breast cancer cells to PI3K/AKT inhibition.","method":"In vitro methyltransferase assay, ChIP, gene expression analysis, siRNA knockdown, pharmacological inhibition, patient-derived organoids","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methylation, ChIP, functional transcriptional and drug sensitivity readouts, single lab","pmids":["38700982"],"is_preprint":false},{"year":2024,"finding":"SMYD2 monomethylates BCAR3 at lysine 334 (K334me1) in breast cancer cells; K334me1 is recognized by a novel methyl-binding domain in FMNL proteins, recruiting them to cell edges to modulate lamellipodia properties and promote cancer cell migration and invasion. Mammary-epithelium-specific SMYD2 ablation blocks metastasis without affecting primary tumor growth.","method":"In vitro methyltransferase assay, site-directed mutagenesis, methyl-binding domain pulldown, live imaging, SMYD2 mammary-specific KO mouse, in vivo metastasis assay","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — in vitro assay, mutagenesis, novel reader identification, in vivo genetic validation, multiple orthogonal methods","pmids":["38296970"],"is_preprint":false},{"year":2024,"finding":"SMYD2 methylates PPARγ, inhibiting its nuclear translocation and transcriptional activity; suppression of PPARγ by SMYD2-mediated methylation promotes mitophagy and PASMC hyperproliferation, contributing to pulmonary hypertension. PPARγ agonist rosiglitazone largely abolishes the detrimental effects of SMYD2 overexpression.","method":"In vitro interaction and methyltransferase assays, SMYD2-vTg mice, LLY-507 pharmacological inhibition, nuclear fractionation, mitophagy assays, hypoxia-induced PH model","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction, methylation, nuclear translocation shown; single lab; multiple in vitro and in vivo approaches","pmids":["38770649"],"is_preprint":false},{"year":2024,"finding":"SMYD2 methylates androgen receptor (AR), promoting AR stability by reducing ubiquitination and proteasomal degradation, thereby enhancing AR transcriptome activity and CRPC resistance to enzalutamide.","method":"Co-IP, in vitro methyltransferase assay, ubiquitination assay, AR transcriptome analysis, siRNA knockdown, AZ505 pharmacological inhibition, mouse xenograft","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — methylation of AR shown, functional ubiquitination/stability consequence, in vivo validation, single lab","pmids":["38243079"],"is_preprint":false}],"current_model":"SMYD2 is a SET/MYND domain lysine methyltransferase that monomethylates a broad range of histone (H3K4, H3K36, H4K20) and non-histone substrates—including p53 (K370), RB (K810/K860), HSP90 (K209/K615, K531/K574), ERα (K266), PARP1 (K528), PTEN (K313), EZH2 (K307), β-catenin (K133), BMPR2, ALK, TRAF2, Ku70, BCAR3 (K334), PPARγ, AR, and c-Myc—using a substrate-binding groove formed between its SET catalytic domain and a TPR-like C-terminal domain (CTD) that undergoes conformational opening upon cofactor binding; in muscle cytoplasm, Smyd2-methylated HSP90 forms a protective complex with titin N2A, and glutathionylation of SMYD2 at Cys13 disrupts this complex to destabilize sarcomeres; CDK4/6 phosphorylates and activates SMYD2, while STUB1 targets it for proteasomal degradation; overall, SMYD2 integrates epigenetic, cytoskeletal, and signaling functions, with substrate methylation outcomes ranging from repression (p53, ERα, PPARγ) to activation (RB phosphorylation, STAT3/NF-κB, BMPR2 kinase, NHEJ repair) depending on context."},"narrative":{"mechanistic_narrative":"SMYD2 is a SET/MYND-domain lysine methyltransferase that monomethylates a broad repertoire of histone and non-histone substrates to control transcription, cell-cycle progression, signaling, and cytoskeletal organization [PMID:17108971, PMID:26750096, PMID:31612581]. Substrate recognition occurs within a peptide-binding groove formed between the catalytic SET domain and a TPR-like C-terminal domain (CTD); the CTD enforces an autoinhibited conformation that opens upon cofactor binding, and a TPR/EDEE motif within it dictates substrate specificity, with target peptides bound in a U-shaped conformation whose specificity is set largely by residues C-terminal to the target lysine [PMID:21782458, PMID:21738746, PMID:21880715, PMID:24594358, PMID:31612581]. On chromatin, SMYD2 deposits repressive or activating marks in a locus-specific manner—H3K36 dimethylation with the Sin3A deacetylase complex and at TNF/IL6 promoters to suppress inflammation, H4K20me1 to recruit the compacting reader L3MBTL1 (including at the latent HIV-1 promoter), and H3K4 methylation at myocardin-bound SMC contractile gene promoters—consistent with predominantly cytoplasmic localization and minimal impact on bulk histone methylation [PMID:16805913, PMID:25825497, PMID:25583990, PMID:28494238, PMID:37615725]. Its dominant role is methylation of non-histone proteins with diverse outcomes: it represses p53 (K370) and ERα (K266) and PPARγ, antagonizing competing acetylation/methylation marks, while methylation of RB (K810/K860) recruits L3MBTL1 and promotes RB phosphorylation and E2F-driven G1/S transit [PMID:17108971, PMID:20870719, PMID:22787429, PMID:24101509, PMID:38770649]. SMYD2 also methylates signaling and stability determinants—PTEN (K313) and ALK to activate AKT, PARP1 (K528), BMPR2 to drive SMAD1/5 signaling, β-catenin (K133) for nuclear import, EZH2 (K307), TRAF2, c-Myc and AR to block their ubiquitin-dependent degradation, and BCAR3 (K334me1) to recruit FMNL proteins and promote migration—several of these driving cancer proliferation, metastasis, and therapy resistance [PMID:24726141, PMID:25925379, PMID:28588028, PMID:28915556, PMID:28370702, PMID:31693890, PMID:34841684, PMID:36611819, PMID:38296970, PMID:38243079]. In striated muscle, SMYD2-methylated HSP90 forms a protective complex with the titin N2A domain, and oxidative glutathionylation of SMYD2 at Cys13 disrupts this complex to destabilize sarcomeres [PMID:22028380, PMID:22241783, PMID:23047121, PMID:30337525, PMID:30190324]. SMYD2 activity is amplified by CDK4/6 phosphorylation and limited by STUB1-mediated proteasomal degradation [PMID:33127671, PMID:35939202].","teleology":[{"year":2006,"claim":"Established SMYD2 as both a histone methyltransferase and a p53 regulator, defining its dual chromatin and non-histone roles from the outset.","evidence":"In vitro methyltransferase assays, Co-IP, and reporter/apoptosis assays showing p53 K370 monomethylation and H3K36me2 with Sin3A association","pmids":["17108971","16805913"],"confidence":"High","gaps":["Genome-wide H3K36 targets not mapped","Physiological balance between histone and p53 activity unclear"]},{"year":2007,"claim":"Showed SMYD2 catalytic output is modulated by partner binding, foreshadowing chaperone-coupled regulation of its activity and specificity.","evidence":"IP-MS, domain-mapping Co-IP, and in vitro methyltransferase assays mapping HSP90α, EBP41L3, and p53 to distinct domains","pmids":["18065756"],"confidence":"Medium","gaps":["Mechanism by which HSP90 shifts specificity to H3K4 unresolved","In vivo relevance of the HSP90 effect not tested"]},{"year":2010,"claim":"Connected SMYD2 methylation to reader-based repression and cell-cycle control by showing RB K860 methylation recruits L3MBTL1.","evidence":"In vitro methyltransferase assay, MS site mapping, and L3MBTL1 methyl-binding domain pulldowns","pmids":["20870719"],"confidence":"High","gaps":["Genomic loci of RB-L3MBTL1 effects not defined","Relationship to RB phosphorylation not yet integrated"]},{"year":2011,"claim":"Defined the structural basis for SMYD2 substrate recognition and autoinhibition, explaining how a single enzyme accommodates diverse substrates and how it can be inhibited.","evidence":"Crystal structures of SMYD2 with p53 peptide, AZ505, SAH/sinefungin, plus CTD/EDEE mutagenesis with functional assays","pmids":["21782458","21738746","21880715"],"confidence":"High","gaps":["Conformational dynamics in solution not directly observed","Structural basis for non-p53 substrate selection still limited"]},{"year":2012,"claim":"Revealed a cytoplasmic, muscle-specific role linking SMYD2-HSP90 methylation to titin stability and contractile function, distinct from chromatin activity.","evidence":"In vitro methyltransferase assays, HSP90 MS site mapping (K209/K615), Co-IP of Smyd2-Hsp90-titin N2A, and zebrafish knockdown muscle/cardiac phenotypes","pmids":["22028380","22241783","23047121"],"confidence":"High","gaps":["Whether HSP90 methylation is strictly required for titin protection not isolated genetically","Mammalian in vivo confirmation limited"]},{"year":2012,"claim":"Showed SMYD2 methylation can be activating by demonstrating RB K810 methylation enhances RB phosphorylation and E2F-driven proliferation, establishing methylation-phosphorylation crosstalk.","evidence":"In vitro/in vivo methylation and phosphorylation assays, LC-MS/MS, E2F reporter, and cell-cycle analysis","pmids":["22787429"],"confidence":"High","gaps":["Mechanism by which K810 methylation promotes adjacent phosphorylation unclear"]},{"year":2013,"claim":"Extended SMYD2 to nuclear hormone receptor control, showing ERα K266 methylation represses estrogen signaling and competes with p300/CBP acetylation.","evidence":"In vitro methyltransferase assay, ChIP, and gene expression analysis in MCF7 cells","pmids":["24101509"],"confidence":"High","gaps":["Demethylase reversing K266me not identified","In vivo endocrine relevance not tested"]},{"year":2014,"claim":"Structurally and biochemically expanded the substrate landscape and chaperone coupling, defining how distinct substrates bind and how HSP90/P23 motifs promote methylation.","evidence":"Crystal structure of SMYD2-ERα peptide, HSP90AB1 K531/K574 MS mapping, PARP1 K528 mapping with PAR assay, and reconstituted MPXL-motif/ERα methylation","pmids":["24594358","24880080","24726141","30190324"],"confidence":"High","gaps":["Quantitative contribution of chaperone scaffolding in cells unresolved","Functional consequences of HSP90 dimerization-site methylation incompletely defined"]},{"year":2015,"claim":"Cemented the dominant non-histone, cytoplasmic identity of SMYD2 and linked it to oncogenic AKT signaling via PTEN K313 methylation.","evidence":"Subcellular fractionation, SILAC proteomics with LLY-507, plus PTEN K313 methylation/mutagenesis and AKT phosphorylation assays","pmids":["25925379","25825497","25583990"],"confidence":"High","gaps":["The small histone subset SMYD2 targets at specific loci not enumerated","PTEN demethylation/turnover not addressed"]},{"year":2016,"claim":"Systematically defined the cellular SMYD2 substrate space, demonstrating broad Kme1 substrate diversity beyond canonical targets.","evidence":"SILAC Kme1 immunoaffinity proteomics with shRNA and LLY-507 orthogonal validation; identification of BTF3, PDAP1, AHNAK/AHNAK2 sites; plus cell-based IP validation of additional substrates with BAY-598","pmids":["26750096","27163177"],"confidence":"High","gaps":["Functional consequences of most newly identified sites untested","Site stoichiometry in vivo unknown"]},{"year":2017,"claim":"Broadened SMYD2 into receptor kinase, Wnt, inflammatory, and chromatin-compaction pathways, showing context-dependent activating and repressive outcomes.","evidence":"In vitro methyltransferase assays and functional readouts for BMPR2/SMAD1-5, ALK/AKT, β-catenin K133 nuclear import, STAT3/NF-κB feedback loops in Pkd1 models, and H4K20me1/L3MBTL1 at the latent HIV-1 promoter","pmids":["28588028","28370702","28915556","28604386","28494238"],"confidence":"Medium","gaps":["Direct kinase-domain methylation sites on receptors not always mapped","Single-lab findings for several pathways"]},{"year":2018,"claim":"Identified redox control of SMYD2 by showing Cys13 glutathionylation disrupts the protective HSP90-titin complex, linking oxidative stress to sarcomere destabilization.","evidence":"Clickable glutathione labeling, Co-IP, and MMP-2/calpain proteolysis assays","pmids":["30337525"],"confidence":"Medium","gaps":["In vivo demonstration of Cys13 glutathionylation in disease lacking","Reversibility/enzymatic deglutathionylation not addressed"]},{"year":2019,"claim":"Refined the SMYD2 recognition motif and linked methylation to protein-stability control of oncogenic substrates.","evidence":"Peptide-array specificity profiling with substrate validation, and EZH2 K307 methylation/stability assays with LSD1 reversal","pmids":["31612581","31693890"],"confidence":"Medium","gaps":["Motif does not predict in-cell methylation reliably","Generality of methylation-stabilization mechanism unclear"]},{"year":2020,"claim":"Placed SMYD2 in a CDK4/6 feedback circuit and extended its activity to tubulin and ciliogenesis, coupling cell-cycle signaling to cytoskeletal dynamics.","evidence":"Kinase and methyltransferase assays, CDK4/6 inhibition, SMYD2 depletion, and cilia assembly assays","pmids":["33127671"],"confidence":"Medium","gaps":["CDK4/6 phosphosite on SMYD2 not mapped","α-tubulin methylation site and stoichiometry undefined"]},{"year":2022,"claim":"Established SMYD2 as a regulator of DNA repair, cell-death, and protein turnover with immune and therapeutic consequences.","evidence":"Ku70 site-specific methylation with NHEJ/cGAS-STING readouts, RIPK1 methylation/death-signaling assays, c-Myc methylation/ubiquitination/GLS1 assays, and STUB1-mediated SMYD2 degradation Co-IP/knockdown","pmids":["37315132","35022391","36611819","35939202"],"confidence":"Medium","gaps":["RIPK1 and SMAD-related methylation sites not all mapped","STUB1 ubiquitination of SMYD2 not reconstituted (Low confidence)"]},{"year":2024,"claim":"Defined SMYD2 as a driver of metastasis and therapy resistance through reader-mediated migration and stabilization of hormone receptors, with mechanism-specific in vivo genetic validation.","evidence":"BCAR3 K334me1/FMNL reader and mammary-specific KO metastasis assays, KMT2D K1330 methylation/ChIP/PI3K-inhibitor sensitization, PPARγ methylation/nuclear translocation in pulmonary hypertension, and AR methylation/stability in CRPC","pmids":["38296970","38700982","38770649","38243079"],"confidence":"Medium","gaps":["Tissue-specific selectivity among these substrates unresolved","Several mechanisms validated in single labs"]},{"year":null,"claim":"It remains unresolved how SMYD2 selects among its many substrates in a given cell type and how its catalytic versus scaffolding functions are partitioned across compartments.","evidence":"No timeline discovery resolves substrate prioritization or compartment-specific function","pmids":[],"confidence":"Medium","gaps":["No quantitative framework for in-cell substrate prioritization","Demethylases for many sites unidentified","Physiological versus oncogenic substrate hierarchy unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,9,11,13,15,18,27]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,7,13,15,21,26,30]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[1,17,35]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,11,35]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16,30,24]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,11,21]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[10,29]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,17,20,35]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,9,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,19,22,23,30]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[26,34,41]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,11,35]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[13,31]}],"complexes":["Sin3A histone deacetylase complex","Smyd2-HSP90-titin N2A complex"],"partners":["HSP90AB1","TP53","RB1","L3MBTL1","ESR1","STUB1","EZH2","BCAR3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NRG4","full_name":"N-lysine methyltransferase SMYD2","aliases":["HSKM-B","Histone methyltransferase SMYD2","Lysine N-methyltransferase 3C","SET and MYND domain-containing protein 2"],"length_aa":433,"mass_kda":49.7,"function":"Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 and RB1. Specifically trimethylates histone H3 'Lys-4' (H3K4me3) in vivo. The activity requires interaction with HSP90alpha. Shows even higher methyltransferase activity on p53/TP53. Monomethylates 'Lys-370' of p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of p53/TP53. Monomethylates RB1 at 'Lys-860'","subcellular_location":"Cytoplasm, cytosol; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NRG4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMYD2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMYD2","total_profiled":1310},"omim":[{"mim_id":"619134","title":"SET AND MYND DOMAIN-CONTAINING PROTEIN 4; SMYD4","url":"https://www.omim.org/entry/619134"},{"mim_id":"610663","title":"SET AND MYND DOMAIN-CONTAINING PROTEIN 2; SMYD2","url":"https://www.omim.org/entry/610663"},{"mim_id":"609132","title":"LYSINE DEMETHYLASE 1A; KDM1A","url":"https://www.omim.org/entry/609132"},{"mim_id":"191170","title":"TUMOR PROTEIN p53; TP53","url":"https://www.omim.org/entry/191170"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Mitochondria","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"heart muscle","ntpm":183.6},{"tissue":"skeletal muscle","ntpm":86.6}],"url":"https://www.proteinatlas.org/search/SMYD2"},"hgnc":{"alias_symbol":["HSKM-B","ZMYND14","KMT3C"],"prev_symbol":[]},"alphafold":{"accession":"Q9NRG4","domains":[{"cath_id":"1.10.220.160","chopping":"40-199","consensus_level":"high","plddt":97.8441,"start":40,"end":199},{"cath_id":"1.25.40.10","chopping":"248-433","consensus_level":"medium","plddt":97.6998,"start":248,"end":433}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NRG4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NRG4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NRG4-F1-predicted_aligned_error_v6.png","plddt_mean":97.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMYD2","jax_strain_url":"https://www.jax.org/strain/search?query=SMYD2"},"sequence":{"accession":"Q9NRG4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NRG4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NRG4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NRG4"}},"corpus_meta":[{"pmid":"17108971","id":"PMC_17108971","title":"Repression of p53 activity by Smyd2-mediated methylation.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17108971","citation_count":521,"is_preprint":false},{"pmid":"16805913","id":"PMC_16805913","title":"Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.","date":"2006","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16805913","citation_count":252,"is_preprint":false},{"pmid":"20870719","id":"PMC_20870719","title":"Methylation of the retinoblastoma tumor suppressor by SMYD2.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20870719","citation_count":181,"is_preprint":false},{"pmid":"22787429","id":"PMC_22787429","title":"RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.","date":"2012","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22787429","citation_count":169,"is_preprint":false},{"pmid":"21782458","id":"PMC_21782458","title":"Structural basis of substrate methylation and inhibition of SMYD2.","date":"2011","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/21782458","citation_count":168,"is_preprint":false},{"pmid":"18065756","id":"PMC_18065756","title":"The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.","date":"2007","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/18065756","citation_count":167,"is_preprint":false},{"pmid":"19423649","id":"PMC_19423649","title":"Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.","date":"2009","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19423649","citation_count":148,"is_preprint":false},{"pmid":"22241783","id":"PMC_22241783","title":"Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization.","date":"2012","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/22241783","citation_count":138,"is_preprint":false},{"pmid":"24101509","id":"PMC_24101509","title":"Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24101509","citation_count":126,"is_preprint":false},{"pmid":"28604386","id":"PMC_28604386","title":"Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28604386","citation_count":108,"is_preprint":false},{"pmid":"25825497","id":"PMC_25825497","title":"LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25825497","citation_count":99,"is_preprint":false},{"pmid":"24726141","id":"PMC_24726141","title":"The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.","date":"2014","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24726141","citation_count":94,"is_preprint":false},{"pmid":"25583990","id":"PMC_25583990","title":"The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25583990","citation_count":92,"is_preprint":false},{"pmid":"22028380","id":"PMC_22028380","title":"Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.","date":"2011","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22028380","citation_count":91,"is_preprint":false},{"pmid":"26750096","id":"PMC_26750096","title":"Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.","date":"2016","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/26750096","citation_count":90,"is_preprint":false},{"pmid":"29487338","id":"PMC_29487338","title":"Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29487338","citation_count":86,"is_preprint":false},{"pmid":"28494238","id":"PMC_28494238","title":"SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency.","date":"2017","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/28494238","citation_count":86,"is_preprint":false},{"pmid":"25321194","id":"PMC_25321194","title":"Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.","date":"2014","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25321194","citation_count":84,"is_preprint":false},{"pmid":"24880080","id":"PMC_24880080","title":"SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/24880080","citation_count":82,"is_preprint":false},{"pmid":"25925379","id":"PMC_25925379","title":"Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.","date":"2015","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25925379","citation_count":81,"is_preprint":false},{"pmid":"31370883","id":"PMC_31370883","title":"Histone methyltransferase SMYD2: ubiquitous regulator of disease.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31370883","citation_count":78,"is_preprint":false},{"pmid":"23047121","id":"PMC_23047121","title":"Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23047121","citation_count":73,"is_preprint":false},{"pmid":"26988419","id":"PMC_26988419","title":"Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/26988419","citation_count":72,"is_preprint":false},{"pmid":"31693890","id":"PMC_31693890","title":"Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31693890","citation_count":71,"is_preprint":false},{"pmid":"27075367","id":"PMC_27075367","title":"Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.","date":"2016","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27075367","citation_count":70,"is_preprint":false},{"pmid":"20305823","id":"PMC_20305823","title":"Cardiac deletion of Smyd2 is dispensable for mouse heart development.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20305823","citation_count":63,"is_preprint":false},{"pmid":"31754403","id":"PMC_31754403","title":"Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31754403","citation_count":58,"is_preprint":false},{"pmid":"21880715","id":"PMC_21880715","title":"Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21880715","citation_count":57,"is_preprint":false},{"pmid":"26101576","id":"PMC_26101576","title":"Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.","date":"2015","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/26101576","citation_count":52,"is_preprint":false},{"pmid":"29856759","id":"PMC_29856759","title":"Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29856759","citation_count":51,"is_preprint":false},{"pmid":"24594358","id":"PMC_24594358","title":"Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.","date":"2014","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24594358","citation_count":49,"is_preprint":false},{"pmid":"29507647","id":"PMC_29507647","title":"SMYD2 promoter DNA methylation is associated with abdominal aortic aneurysm (AAA) and SMYD2 expression in vascular smooth muscle cells.","date":"2018","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/29507647","citation_count":44,"is_preprint":false},{"pmid":"33935284","id":"PMC_33935284","title":"SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33935284","citation_count":40,"is_preprint":false},{"pmid":"33127671","id":"PMC_33127671","title":"Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33127671","citation_count":40,"is_preprint":false},{"pmid":"28915556","id":"PMC_28915556","title":"Critical roles of SMYD2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28915556","citation_count":40,"is_preprint":false},{"pmid":"38770649","id":"PMC_38770649","title":"SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy.","date":"2024","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/38770649","citation_count":39,"is_preprint":false},{"pmid":"25014164","id":"PMC_25014164","title":"Lysine methyltransferase Smyd2 suppresses p53-dependent cardiomyocyte apoptosis.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25014164","citation_count":39,"is_preprint":false},{"pmid":"28370702","id":"PMC_28370702","title":"Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.","date":"2017","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/28370702","citation_count":36,"is_preprint":false},{"pmid":"21738746","id":"PMC_21738746","title":"Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21738746","citation_count":36,"is_preprint":false},{"pmid":"30998113","id":"PMC_30998113","title":"Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.","date":"2019","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30998113","citation_count":33,"is_preprint":false},{"pmid":"30337525","id":"PMC_30337525","title":"SMYD2 glutathionylation contributes to degradation of sarcomeric proteins.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30337525","citation_count":31,"is_preprint":false},{"pmid":"31106145","id":"PMC_31106145","title":"Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31106145","citation_count":31,"is_preprint":false},{"pmid":"34841684","id":"PMC_34841684","title":"SMYD2-mediated TRAF2 methylation promotes the NF-κB signaling pathways in inflammatory diseases.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34841684","citation_count":30,"is_preprint":false},{"pmid":"32266106","id":"PMC_32266106","title":"SMYD2 suppresses APC2 expression to activate the Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32266106","citation_count":30,"is_preprint":false},{"pmid":"28002961","id":"PMC_28002961","title":"Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.","date":"2016","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28002961","citation_count":30,"is_preprint":false},{"pmid":"25562686","id":"PMC_25562686","title":"The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25562686","citation_count":30,"is_preprint":false},{"pmid":"35022391","id":"PMC_35022391","title":"SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35022391","citation_count":29,"is_preprint":false},{"pmid":"37315132","id":"PMC_37315132","title":"SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37315132","citation_count":28,"is_preprint":false},{"pmid":"37121971","id":"PMC_37121971","title":"Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis.","date":"2023","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37121971","citation_count":27,"is_preprint":false},{"pmid":"30955858","id":"PMC_30955858","title":"Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30955858","citation_count":27,"is_preprint":false},{"pmid":"34544413","id":"PMC_34544413","title":"LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34544413","citation_count":27,"is_preprint":false},{"pmid":"36611819","id":"PMC_36611819","title":"SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36611819","citation_count":26,"is_preprint":false},{"pmid":"31548876","id":"PMC_31548876","title":"SMYD2 promotes cervical cancer growth by stimulating cell proliferation.","date":"2019","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/31548876","citation_count":26,"is_preprint":false},{"pmid":"23873367","id":"PMC_23873367","title":"SMYD2 is induced during cell differentiation and participates in early development.","date":"2013","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23873367","citation_count":26,"is_preprint":false},{"pmid":"26826421","id":"PMC_26826421","title":"SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26826421","citation_count":26,"is_preprint":false},{"pmid":"28588028","id":"PMC_28588028","title":"The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28588028","citation_count":26,"is_preprint":false},{"pmid":"26790435","id":"PMC_26790435","title":"Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26790435","citation_count":25,"is_preprint":false},{"pmid":"31040701","id":"PMC_31040701","title":"SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31040701","citation_count":24,"is_preprint":false},{"pmid":"34143514","id":"PMC_34143514","title":"Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34143514","citation_count":24,"is_preprint":false},{"pmid":"27163177","id":"PMC_27163177","title":"An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates.","date":"2016","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/27163177","citation_count":24,"is_preprint":false},{"pmid":"35297562","id":"PMC_35297562","title":"Histone methyltransferase Smyd2 contributes to blood-brain barrier breakdown in stroke.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35297562","citation_count":22,"is_preprint":false},{"pmid":"38110168","id":"PMC_38110168","title":"Neutrophil extracellular traps promote gastric cancer cell metastasis via the NAT10-mediated N4-acetylcytidine modification of SMYD2.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38110168","citation_count":22,"is_preprint":false},{"pmid":"35884603","id":"PMC_35884603","title":"Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35884603","citation_count":21,"is_preprint":false},{"pmid":"34015314","id":"PMC_34015314","title":"SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34015314","citation_count":20,"is_preprint":false},{"pmid":"35503397","id":"PMC_35503397","title":"Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer.","date":"2022","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/35503397","citation_count":20,"is_preprint":false},{"pmid":"19003161","id":"PMC_19003161","title":"smyd1 and smyd2 are expressed in muscle tissue in Xenopus laevis.","date":"2008","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/19003161","citation_count":20,"is_preprint":false},{"pmid":"38296970","id":"PMC_38296970","title":"Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis.","date":"2024","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38296970","citation_count":19,"is_preprint":false},{"pmid":"35759739","id":"PMC_35759739","title":"Cross talk between lysine methyltransferase Smyd2 and TGF-β-Smad3 signaling promotes renal fibrosis in autosomal dominant polycystic kidney disease.","date":"2022","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35759739","citation_count":19,"is_preprint":false},{"pmid":"31348575","id":"PMC_31348575","title":"SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.","date":"2019","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/31348575","citation_count":19,"is_preprint":false},{"pmid":"31612581","id":"PMC_31612581","title":"Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.","date":"2019","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31612581","citation_count":19,"is_preprint":false},{"pmid":"32934721","id":"PMC_32934721","title":"The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32934721","citation_count":19,"is_preprint":false},{"pmid":"27655694","id":"PMC_27655694","title":"Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27655694","citation_count":18,"is_preprint":false},{"pmid":"35142600","id":"PMC_35142600","title":"Ranunculus ternatus Thunb extract attenuates renal fibrosis of diabetic nephropathy via inhibiting SMYD2.","date":"2022","source":"Pharmaceutical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35142600","citation_count":18,"is_preprint":false},{"pmid":"30190324","id":"PMC_30190324","title":"A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor α methylation by the lysine methyltransferase SMYD2.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30190324","citation_count":18,"is_preprint":false},{"pmid":"38322347","id":"PMC_38322347","title":"The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3-SRF axis.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/38322347","citation_count":17,"is_preprint":false},{"pmid":"28187429","id":"PMC_28187429","title":"SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28187429","citation_count":17,"is_preprint":false},{"pmid":"35914250","id":"PMC_35914250","title":"Protein Lysine Methyltransferase SMYD2: A Promising Small Molecule Target for Cancer Therapy.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35914250","citation_count":16,"is_preprint":false},{"pmid":"32096186","id":"PMC_32096186","title":"LncRNA NEAT1 promotes cardiac hypertrophy through microRNA-19a-3p/SMYD2 axis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32096186","citation_count":16,"is_preprint":false},{"pmid":"32342276","id":"PMC_32342276","title":"SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.","date":"2020","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32342276","citation_count":15,"is_preprint":false},{"pmid":"36191822","id":"PMC_36191822","title":"The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/36191822","citation_count":15,"is_preprint":false},{"pmid":"38243079","id":"PMC_38243079","title":"Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38243079","citation_count":14,"is_preprint":false},{"pmid":"36046818","id":"PMC_36046818","title":"Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36046818","citation_count":14,"is_preprint":false},{"pmid":"37478669","id":"PMC_37478669","title":"Long noncoding RNA DLEU1 promotes proliferation and glycolysis of gastric cancer cells via APOC1 upregulation by recruiting SMYD2 to induce trimethylation of H3K4 modification.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37478669","citation_count":14,"is_preprint":false},{"pmid":"34510321","id":"PMC_34510321","title":"Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34510321","citation_count":13,"is_preprint":false},{"pmid":"37036190","id":"PMC_37036190","title":"Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.","date":"2023","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/37036190","citation_count":12,"is_preprint":false},{"pmid":"35939202","id":"PMC_35939202","title":"STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.","date":"2022","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/35939202","citation_count":12,"is_preprint":false},{"pmid":"35432530","id":"PMC_35432530","title":"Baicalein Inhibits the SMYD2/RPS7 Signaling Pathway to Inhibit the Occurrence and Metastasis of Lung Cancer.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35432530","citation_count":12,"is_preprint":false},{"pmid":"38700982","id":"PMC_38700982","title":"Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38700982","citation_count":11,"is_preprint":false},{"pmid":"35668081","id":"PMC_35668081","title":"SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35668081","citation_count":11,"is_preprint":false},{"pmid":"27959541","id":"PMC_27959541","title":"Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.","date":"2016","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/27959541","citation_count":11,"is_preprint":false},{"pmid":"26717235","id":"PMC_26717235","title":"Molecular Dynamics Simulation Reveals Correlated Inter-Lobe Motion in Protein Lysine Methyltransferase SMYD2.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26717235","citation_count":11,"is_preprint":false},{"pmid":"37615725","id":"PMC_37615725","title":"SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37615725","citation_count":10,"is_preprint":false},{"pmid":"36270984","id":"PMC_36270984","title":"Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36270984","citation_count":9,"is_preprint":false},{"pmid":"37524453","id":"PMC_37524453","title":"Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation.","date":"2023","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37524453","citation_count":9,"is_preprint":false},{"pmid":"39940255","id":"PMC_39940255","title":"The Olive Oil Phenolic S-(-)-Oleocanthal Suppresses Colorectal Cancer Progression and Recurrence by Modulating SMYD2-EZH2 and c-MET Activation.","date":"2025","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/39940255","citation_count":9,"is_preprint":false},{"pmid":"18601734","id":"PMC_18601734","title":"Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.","date":"2008","source":"Acta veterinaria Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/18601734","citation_count":9,"is_preprint":false},{"pmid":"33011288","id":"PMC_33011288","title":"Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.","date":"2020","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/33011288","citation_count":8,"is_preprint":false},{"pmid":"32115575","id":"PMC_32115575","title":"The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias.","date":"2020","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32115575","citation_count":8,"is_preprint":false},{"pmid":"35637161","id":"PMC_35637161","title":"SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth.","date":"2022","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35637161","citation_count":7,"is_preprint":false},{"pmid":"35455942","id":"PMC_35455942","title":"SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35455942","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50880,"output_tokens":9740,"usd":0.14937,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20016,"output_tokens":5743,"usd":0.121828,"stage2_stop_reason":"end_turn"},"total_usd":0.271198,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"SMYD2 methylates p53 at lysine 370 (monomethylation), repressing p53-mediated transcriptional activity. Set9-mediated methylation of p53 K372 inhibits SMYD2-mediated K370 methylation in part by blocking the p53-SMYD2 interaction, establishing cross-talk between activating and repressing lysine methylation marks on p53.\",\n      \"method\": \"In vitro methyltransferase assay, siRNA knockdown, co-immunoprecipitation, apoptosis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — in vitro methyltransferase assay plus interaction studies, replicated across multiple labs subsequently\",\n      \"pmids\": [\"17108971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SMYD2 mediates histone H3K36 dimethylation via its SET domain, represses transcription from a reporter, and associates specifically with the Sin3A histone deacetylase complex. Overexpressed SMYD2 localizes to both cytoplasm and nucleus.\",\n      \"method\": \"Histone methyltransferase assay, co-immunoprecipitation with Sin3A complex, reporter gene assay, subcellular localization by immunofluorescence\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 / Moderate — in vitro HMT assay and Co-IP, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"16805913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SMYD2 interacts with HSP90α independently of its SET and MYND domains, and this interaction enhances SMYD2 histone methyltransferase activity and specificity for H3K4 in vitro. SMYD2 interacts with EBP41L3 through the MYND domain and with p53 through the SET domain.\",\n      \"method\": \"Immunoprecipitation coupled to mass spectrometry, co-immunoprecipitation, in vitro methyltransferase assay, chromatin IP\",\n      \"journal\": \"Molecular & cellular proteomics : MCP\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and domain-mapping experiments, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18065756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SMYD2 methylates RB at lysine 860 in vitro and in cells; this monomethylation provides a direct binding site for the methyl-binding domain of the transcriptional repressor L3MBTL1. Methylation is regulated during cell cycle progression, differentiation, and in response to DNA damage.\",\n      \"method\": \"In vitro methyltransferase assay, mass spectrometry, pulldown with L3MBTL1 methyl-binding domain, cell-cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro assay, MS-confirmed site, biochemical reader recruitment, independently confirmed by subsequent studies\",\n      \"pmids\": [\"20870719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structures of SMYD2 in complex with p53 substrate and product peptides, and with the inhibitor AZ505, reveal that the substrate (p53 peptide) binds in the peptide-binding groove between the SET domain and C-terminal domain (CTD), and that AZ505 is a substrate-competitive inhibitor occupying this same groove.\",\n      \"method\": \"X-ray crystallography, high-throughput chemical screen, biochemical inhibition assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with bound substrate peptides and inhibitor, replicated by multiple subsequent structural studies\",\n      \"pmids\": [\"21782458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structures of SMYD2 bound to cofactor product S-adenosylhomocysteine or inhibitor sinefungin reveal that the CTD stabilizes an autoinhibited conformation and restricts access to the catalytic site; sinefungin binding causes outward bending of the first two CTD helices, demonstrating conformational flexibility of the TPR-like CTD.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures with two different ligands revealing conformational change, single lab\",\n      \"pmids\": [\"21738746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of full-length SMYD2 in complex with SAM cofactor and p53 peptide shows the substrate binds in a U-shaped conformation in a deep pocket between the SET domain and CTD. The tetratricopeptide repeat (TPR) motif of the CTD and an EDEE motif are critical for p53 substrate binding specificity; deletion of CTD or mutation of EDEE impairs SMYD2 methylation of p53.\",\n      \"method\": \"X-ray crystallography, domain deletion and site-directed mutagenesis, in vitro methyltransferase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis with functional validation in one study\",\n      \"pmids\": [\"21880715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SMYD2 methylates HSP90 at K209 and K615 (nucleotide-binding and dimerization domains, respectively); each methylation site shows unique reactivity to HSP90 co-chaperones, pH, and demethylation by LSD1.\",\n      \"method\": \"Proteomic interactome mapping, Co-IP, in vitro methyltransferase assay, mass spectrometry\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-confirmed methylation sites and biochemical characterization, single lab\",\n      \"pmids\": [\"22028380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SMYD2 methylates the cytoplasmic chaperone HSP90 in multiple cell types; in muscle, HSP90 methylation promotes formation of a Smyd2–Hsp90–titin (N2A domain) complex. Smyd2 deficiency causes loss of Hsp90 methylation, impaired titin stability, and altered skeletal muscle function.\",\n      \"method\": \"In vitro methyltransferase assay, co-immunoprecipitation, zebrafish morpholino knockdown, muscle function assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — in vitro assay, Co-IP complex, in vivo loss-of-function with functional phenotype\",\n      \"pmids\": [\"22241783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SMYD2 methylates RB1 at lysine 810 (identified by LC-MS/MS); this methylation enhances Ser807/811 phosphorylation of RB1 both in vitro and in vivo, accelerates E2F transcriptional activity, and promotes G1/S cell cycle progression.\",\n      \"method\": \"In vitro methyltransferase assay, LC-MS/MS, in vivo methylation/phosphorylation assays, E2F reporter, cell cycle analysis, siRNA knockdown\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — MS-confirmed site, in vitro and in vivo functional validation, crosstalk with phosphorylation demonstrated\",\n      \"pmids\": [\"22787429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Smyd2 associates with the sarcomeric I-band at the titin N2A domain in cardiomyocytes; binding to N2A occurs in vitro and in yeast via N-terminal and extreme C-terminal regions of Smyd2. Smyd2 knockdown in zebrafish strongly impairs cardiac performance.\",\n      \"method\": \"In vitro binding assay, yeast two-hybrid, zebrafish morpholino knockdown, cardiac function measurement\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding, yeast two-hybrid domain mapping, in vivo cardiac phenotype in zebrafish\",\n      \"pmids\": [\"23047121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SMYD2 directly methylates ERα at lysine 266 (K266) in vitro and in MCF7 cells; this methylation attenuates chromatin recruitment of ERα and represses ERα target gene activation under estrogen-depleted conditions. Upon estrogen stimulation, K266 methylation is diminished, enabling p300/CBP to acetylate K266 and promote ERα transactivation, establishing cross-talk between SMYD2-mediated methylation and acetylation.\",\n      \"method\": \"In vitro methyltransferase assay, chromatin immunoprecipitation, gene expression analysis, siRNA knockdown\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — in vitro assay, ChIP, functional gene expression data, crosstalk mechanism defined\",\n      \"pmids\": [\"24101509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structure of SMYD2 in complex with an ERα K266-containing peptide shows ERα binds in a U-shaped conformation with binding specificity determined mainly by residues C-terminal to the target lysine. Comparison with SMYD2–p53 structure reveals distinct substrate binding modes underlying SMYD2's broad substrate specificity.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with structural comparison, single lab\",\n      \"pmids\": [\"24594358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SMYD2 monomethylates PARP1 at lysine 528 (confirmed by LC-MS/MS and Edman degradation); methylated PARP1 shows enhanced poly(ADP-ribose) formation after oxidative stress, positively regulating PARP1 poly(ADP-ribosyl)ation activity.\",\n      \"method\": \"In vitro methyltransferase assay, LC-MS/MS, Edman degradation, PAR formation assay\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — MS-confirmed methylation site, functional enzymatic activity assay, single lab\",\n      \"pmids\": [\"24726141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SMYD2 methylates HSP90AB1 at lysines 531 and 574; these methylation sites are important for HSP90AB1 dimerization and chaperone complex formation. HSP90AB1 interacts with SMYD2 through the C-terminal region of HSP90AB1 and the SET domain of SMYD2.\",\n      \"method\": \"In vitro and in vivo methyltransferase assays, mass spectrometry, co-immunoprecipitation, proliferation assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 / Moderate — MS-confirmed sites, biochemical domain mapping, single lab\",\n      \"pmids\": [\"24880080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SMYD2 methylates PTEN at lysine 313 in vitro and in vivo; K313 methylation negatively regulates PTEN tumor suppressor activity, attenuates PTEN S380 phosphorylation, and results in AKT pathway activation. SMYD2 knockdown reduces AKT phosphorylation in breast cancer cells.\",\n      \"method\": \"In vitro methyltransferase assay, MS confirmation, site-directed mutagenesis (K313A), phosphorylation assays, siRNA knockdown\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Moderate — in vitro assay, mutagenesis, in vivo functional validation, single lab\",\n      \"pmids\": [\"25925379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SMYD2 is primarily cytoplasmic by subcellular fractionation; inhibition with LLY-507 does not significantly affect global histone methylation levels (by MS-based proteomics), suggesting SMYD2 targets non-histone substrates or a small subset of histones at specific loci.\",\n      \"method\": \"Subcellular fractionation, SILAC-based mass spectrometry, selective inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation and quantitative proteomics, single lab, two orthogonal methods\",\n      \"pmids\": [\"25825497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Smyd2 specifically facilitates H3K36 dimethylation at TNF and IL6 gene promoters in macrophages, suppressing their transcription and inhibiting NF-κB and ERK signaling, resulting in reduced macrophage activation and M1 polarization.\",\n      \"method\": \"ChIP assay, siRNA knockdown, cytokine measurement, signaling pathway analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming H3K36me2 at specific promoters, functional cytokine output, single lab\",\n      \"pmids\": [\"25583990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SILAC-based proteomics identified 35 cellular monomethyl-lysine (Kme1) sites potently down-regulated by both shRNA knockdown and the selective SMYD2 inhibitor LLY-507 in ESCC cells, including BTF3-K2, PDAP1-K126, and numerous sites in AHNAK and AHNAK2, revealing diverse SMYD2 substrate specificity in cells.\",\n      \"method\": \"SILAC, immunoaffinity enrichment of Kme1 peptides, mass spectrometry, shRNA knockdown, small molecule inhibitor\",\n      \"journal\": \"Molecular & cellular proteomics : MCP\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — quantitative proteomics with orthogonal genetic and chemical validation, large-scale rigorous study\",\n      \"pmids\": [\"26750096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SMYD2 was identified as essential for robust BMP- (but not TGFβ-) induced target gene expression; SMYD2 methylates the kinase domain of BMPR2 (BMP type II receptor), promoting BMPR2 kinase activity and downstream SMAD1/5 phosphorylation and nuclear localization.\",\n      \"method\": \"RNAi screen, CRISPR/Cas9 knockout, shRNA knockdown, in vitro methyltransferase assay, SMAD1/5 phosphorylation assays, nuclear localization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methyltransferase assay of BMPR2, genetic validation by KD/KO, functional signaling readout, single lab\",\n      \"pmids\": [\"28588028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD2 associates with latent HIV-1 promoter chromatin enriched in H4K20me1; SMYD2 knockdown or pharmacological inhibition reactivates latent HIV-1 in T cells. L3MBTL1, a chromatin-compacting H4K20me1 reader, is recruited to the latent HIV-1 promoter in a SMYD2-dependent manner.\",\n      \"method\": \"RNAi screen, pharmacological inhibition, chromatin immunoprecipitation, HIV latency reactivation assay\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP showing SMYD2 and H4K20me1 at HIV promoter, L3MBTL1 recruitment, functional reactivation assay, single lab\",\n      \"pmids\": [\"28494238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD2 methylates β-catenin at lysine 133; K133 methylation is critical for β-catenin nuclear translocation and interaction with FOXM1. K133A substitution almost completely abolishes nuclear localization. SMYD2 knockdown reduces nuclear β-catenin and downstream Wnt target gene expression.\",\n      \"method\": \"In vitro methyltransferase assay, site-directed mutagenesis (K133A), nuclear fractionation, co-immunoprecipitation, gene expression analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus localization studies and CoIP, single lab\",\n      \"pmids\": [\"28915556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD2 methylates ALK at lysines 1451, 1455, and 1610; K1610A substitution reduces AKT phosphorylation and cell growth, and SMYD2 knockdown attenuates EML4-ALK phosphorylation in NSCLC cells.\",\n      \"method\": \"In vitro methyltransferase assay, site-directed mutagenesis, phosphorylation assays, siRNA knockdown, cell proliferation assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro assay, mutagenesis with functional readout, single lab\",\n      \"pmids\": [\"28370702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD2 carries out its pro-cystic function via methylation and activation of STAT3 and the p65 subunit of NF-κB, leading to increased renal epithelial cell proliferation and survival. Two positive feedback loops were identified: SMYD2/IL-6/STAT3/SMYD2 and SMYD2/TNF-α/NF-κB/SMYD2.\",\n      \"method\": \"In vivo Pkd1 knockout mouse models, pharmacological inhibition with AZ505, in vitro methyltransferase assay, signaling pathway analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic and pharmacological models, biochemical substrate methylation, single lab\",\n      \"pmids\": [\"28604386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SMYD2 glutathionylation at Cys13 (identified by clickable glutathione approach) causes loss of its interaction with Hsp90 and the titin N2A domain. Upon dissociation, titin/N2A is degraded by activated MMP-2, establishing a mechanism by which ROS-induced SMYD2 glutathionylation leads to sarcomere destabilization.\",\n      \"method\": \"Clickable glutathione labeling, biochemical Co-IP, proteolysis assays with MMP-2 and calpain 1\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel chemical biology method for glutathionylation site, biochemical functional consequence, single lab\",\n      \"pmids\": [\"30337525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HSP90 and co-chaperone P23 contain a (M/I/L/V)PXL motif at their C-termini that mediates interaction with SMYD2 independently of the HSP90 EEVD motif. In a reconstituted bacterial system, SMYD2 binding to HSP90/P23 considerably increases methylation of ERα K266, linking chaperone complex formation to ERα methylation efficiency.\",\n      \"method\": \"Alpha proximity assay, synthetic peptide competition, bacterial reconstitution system, in vitro methyltransferase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 / Moderate — reconstituted system with defined motif, functional methylation assay, single lab\",\n      \"pmids\": [\"30190324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMYD2 directly methylates EZH2 at lysine 307 (K307), enhancing EZH2 protein stability; LSD1 can reverse this methylation. SMYD2-mediated EZH2 K307 methylation promotes breast cancer cell proliferation, EMT, and invasion through stabilized EZH2 function.\",\n      \"method\": \"In vitro methyltransferase assay, mass spectrometry, co-immunoprecipitation, protein stability assay, siRNA knockdown\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methylation, MS confirmation, LSD1 demethylation, single lab\",\n      \"pmids\": [\"31693890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Peptide array profiling of SMYD2 substrate specificity revealed preference for leucine (or phenylalanine) at the -1 position and disfavor of acidic residues at +1 to +3 positions; using this motif, 32 novel peptide substrates and 14 novel protein substrates were identified by in vitro methyltransferase assays.\",\n      \"method\": \"Peptide arrays, in vitro methyltransferase assays\",\n      \"journal\": \"Chembiochem\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic peptide array plus protein-level validation, single lab\",\n      \"pmids\": [\"31612581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Six novel SMYD2 substrates (MAPT, CCAR2, EEF2, NCOA3, STUB1, UTP14A) were confirmed by immunoprecipitation in cells; methylation was abrogated by the selective SMYD2 inhibitor BAY-598, confirming dependence on SMYD2 catalytic activity.\",\n      \"method\": \"Bioinformatic prediction, co-immunoprecipitation, selective inhibitor treatment\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cell-based IP with chemical probe validation across multiple substrates, single lab\",\n      \"pmids\": [\"27163177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK4/6 directly phosphorylates SMYD2, positively regulating its enzymatic activity; SMYD2 in turn positively regulates CDK4/6 expression. SMYD2 functions as an α-tubulin methyltransferase, connecting CDK4/6-SMYD2 signaling to microtubule dynamics and ciliogenesis.\",\n      \"method\": \"Kinase assay, in vitro methyltransferase assay, CDK4/6 inhibitor treatment, SMYD2 depletion, cilia assembly assay\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase and methyltransferase assays, genetic depletion with functional cilia phenotype, single lab\",\n      \"pmids\": [\"33127671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SMYD2 methylates TRAF2 in the cytoplasm; SMYD2-mediated TRAF2 methylation stabilizes TRAF2 against proteolysis and enhances NF-κB signaling activity. LSD1 demethylates TRAF2 to counteract this modification.\",\n      \"method\": \"Mass spectrometry, pulldown, co-immunoprecipitation, methyltransferase assay, ubiquitination assay, luciferase reporter, in vivo inflammation models\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-confirmed methylation, multiple biochemical assays, single lab\",\n      \"pmids\": [\"34841684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMYD2 methylates Ku70 at lysines 74, 516, and 539 in response to DNA damage, leading to increased recruitment of the Ku70/Ku80/DNA-PKcs complex to DNA damage sites and promoting NHEJ repair. SMYD2 inhibition causes persistent DNA damage, cytosolic DNA accumulation, and activation of the cGAS-STING pathway with increased CD8+ T cell infiltration.\",\n      \"method\": \"Co-IP, in vitro methyltransferase assay (Ku70), DNA damage response assays, cGAS-STING pathway analysis, immune cell profiling\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-specific methylation and NHEJ complex recruitment demonstrated, immune pathway functional consequence, single lab\",\n      \"pmids\": [\"37315132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMYD2 methylates RIPK1 and inhibits RIPK1 phosphorylation, thereby restricting TNF-induced apoptosis and necroptosis in colon tumor cells and supporting tumor growth.\",\n      \"method\": \"SMYD2 deficiency experiments, RIPK1 phosphorylation assays, apoptosis/necroptosis assays, tumor growth models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined signaling phenotype (RIPK1 phosphorylation), single lab\",\n      \"pmids\": [\"35022391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STUB1 (an E3 ubiquitin ligase) mediates ubiquitin-dependent degradation of SMYD2 in response to cisplatin treatment; STUB1 knockdown reverses SMYD2 degradation and impairs cisplatin efficacy in glioma cells.\",\n      \"method\": \"UbiBrowser prediction, co-IP, siRNA knockdown, protein stability assay\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and knockdown experiment, no direct ubiquitination reconstitution shown in abstract\",\n      \"pmids\": [\"35939202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMYD2 methylates c-Myc to increase its protein stability by reducing K48-linked polyubiquitination and proteasomal degradation; stabilized c-Myc upregulates GLS1, promoting glutamine metabolism in hepatocellular carcinoma.\",\n      \"method\": \"Co-IP, ubiquitination assay, in vitro methyltransferase assay, siRNA knockdown, gene expression analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methyltransferase assay, ubiquitination changes, metabolic functional readout, single lab\",\n      \"pmids\": [\"36611819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMYD2 regulates VSMC contractile phenotype by promoting expression and transactivation of myocardin; myocardin directly interacts with SMYD2 and facilitates SMYD2 recruitment to CArG regions of SMC contractile gene promoters, where SMYD2-mediated H3K4 methylation creates an open chromatin state. SMYD2 ablation in VSMCs exacerbates neointima formation.\",\n      \"method\": \"SMC-specific SMYD2 knockout mice, genome-wide transcriptome analysis, ChIP, Co-IP, carotid artery injury model\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — SMC-specific KO in vivo plus ChIP and CoIP defining mechanism, single lab\",\n      \"pmids\": [\"37615725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMYD2 directly methylates SMAD3, and epigenetic regulation by SMYD2 upregulates SMAD3 expression, thereby promoting lung cancer metastasis. SMYD2 knockdown reduces SMAD3 levels and cell migration/invasion.\",\n      \"method\": \"siRNA knockdown, in vitro EMT system, ChIP, in vivo metastasis models\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and KD showing transcriptional regulation; direct methylation of SMAD3 not definitively established in abstract\",\n      \"pmids\": [\"37121971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMYD2 promotes HDAC3 expression via H3K36 trimethylation at the HDAC3 promoter; HDAC3 then directly interacts with and deacetylates SRF, enhancing SRF transcriptional activity and VSMC proliferation. SMYD2 knockdown represses SRF target genes and inhibits neointima formation.\",\n      \"method\": \"Transcriptome sequencing, ChIP, Co-IP, Smyd2-vTg mouse, carotid injury model, HDAC3 inhibitor studies\",\n      \"journal\": \"Acta pharmaceutica sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming H3K36me3 at HDAC3 promoter, Co-IP of HDAC3-SRF, in vivo model, single lab\",\n      \"pmids\": [\"38322347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD2 methylates KMT2D at K1330, adjacent to the PI3K-regulated S1331 phosphorylation site; K1330 methylation promotes KMT2D chromatin binding. SMYD2 loss attenuates alpelisib-induced KMT2D binding and ERα-dependent transcription, and sensitizes ER+ breast cancer cells to PI3K/AKT inhibition.\",\n      \"method\": \"In vitro methyltransferase assay, ChIP, gene expression analysis, siRNA knockdown, pharmacological inhibition, patient-derived organoids\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methylation, ChIP, functional transcriptional and drug sensitivity readouts, single lab\",\n      \"pmids\": [\"38700982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD2 monomethylates BCAR3 at lysine 334 (K334me1) in breast cancer cells; K334me1 is recognized by a novel methyl-binding domain in FMNL proteins, recruiting them to cell edges to modulate lamellipodia properties and promote cancer cell migration and invasion. Mammary-epithelium-specific SMYD2 ablation blocks metastasis without affecting primary tumor growth.\",\n      \"method\": \"In vitro methyltransferase assay, site-directed mutagenesis, methyl-binding domain pulldown, live imaging, SMYD2 mammary-specific KO mouse, in vivo metastasis assay\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — in vitro assay, mutagenesis, novel reader identification, in vivo genetic validation, multiple orthogonal methods\",\n      \"pmids\": [\"38296970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD2 methylates PPARγ, inhibiting its nuclear translocation and transcriptional activity; suppression of PPARγ by SMYD2-mediated methylation promotes mitophagy and PASMC hyperproliferation, contributing to pulmonary hypertension. PPARγ agonist rosiglitazone largely abolishes the detrimental effects of SMYD2 overexpression.\",\n      \"method\": \"In vitro interaction and methyltransferase assays, SMYD2-vTg mice, LLY-507 pharmacological inhibition, nuclear fractionation, mitophagy assays, hypoxia-induced PH model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction, methylation, nuclear translocation shown; single lab; multiple in vitro and in vivo approaches\",\n      \"pmids\": [\"38770649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD2 methylates androgen receptor (AR), promoting AR stability by reducing ubiquitination and proteasomal degradation, thereby enhancing AR transcriptome activity and CRPC resistance to enzalutamide.\",\n      \"method\": \"Co-IP, in vitro methyltransferase assay, ubiquitination assay, AR transcriptome analysis, siRNA knockdown, AZ505 pharmacological inhibition, mouse xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — methylation of AR shown, functional ubiquitination/stability consequence, in vivo validation, single lab\",\n      \"pmids\": [\"38243079\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMYD2 is a SET/MYND domain lysine methyltransferase that monomethylates a broad range of histone (H3K4, H3K36, H4K20) and non-histone substrates—including p53 (K370), RB (K810/K860), HSP90 (K209/K615, K531/K574), ERα (K266), PARP1 (K528), PTEN (K313), EZH2 (K307), β-catenin (K133), BMPR2, ALK, TRAF2, Ku70, BCAR3 (K334), PPARγ, AR, and c-Myc—using a substrate-binding groove formed between its SET catalytic domain and a TPR-like C-terminal domain (CTD) that undergoes conformational opening upon cofactor binding; in muscle cytoplasm, Smyd2-methylated HSP90 forms a protective complex with titin N2A, and glutathionylation of SMYD2 at Cys13 disrupts this complex to destabilize sarcomeres; CDK4/6 phosphorylates and activates SMYD2, while STUB1 targets it for proteasomal degradation; overall, SMYD2 integrates epigenetic, cytoskeletal, and signaling functions, with substrate methylation outcomes ranging from repression (p53, ERα, PPARγ) to activation (RB phosphorylation, STAT3/NF-κB, BMPR2 kinase, NHEJ repair) depending on context.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMYD2 is a SET/MYND-domain lysine methyltransferase that monomethylates a broad repertoire of histone and non-histone substrates to control transcription, cell-cycle progression, signaling, and cytoskeletal organization [#0, #18, #27]. Substrate recognition occurs within a peptide-binding groove formed between the catalytic SET domain and a TPR-like C-terminal domain (CTD); the CTD enforces an autoinhibited conformation that opens upon cofactor binding, and a TPR/EDEE motif within it dictates substrate specificity, with target peptides bound in a U-shaped conformation whose specificity is set largely by residues C-terminal to the target lysine [#4, #5, #6, #12, #27]. On chromatin, SMYD2 deposits repressive or activating marks in a locus-specific manner\\u2014H3K36 dimethylation with the Sin3A deacetylase complex and at TNF/IL6 promoters to suppress inflammation, H4K20me1 to recruit the compacting reader L3MBTL1 (including at the latent HIV-1 promoter), and H3K4 methylation at myocardin-bound SMC contractile gene promoters\\u2014consistent with predominantly cytoplasmic localization and minimal impact on bulk histone methylation [#1, #16, #17, #20, #35]. Its dominant role is methylation of non-histone proteins with diverse outcomes: it represses p53 (K370) and ER\\u03b1 (K266) and PPAR\\u03b3, antagonizing competing acetylation/methylation marks, while methylation of RB (K810/K860) recruits L3MBTL1 and promotes RB phosphorylation and E2F-driven G1/S transit [#0, #3, #9, #11, #40]. SMYD2 also methylates signaling and stability determinants\\u2014PTEN (K313) and ALK to activate AKT, PARP1 (K528), BMPR2 to drive SMAD1/5 signaling, \\u03b2-catenin (K133) for nuclear import, EZH2 (K307), TRAF2, c-Myc and AR to block their ubiquitin-dependent degradation, and BCAR3 (K334me1) to recruit FMNL proteins and promote migration\\u2014several of these driving cancer proliferation, metastasis, and therapy resistance [#13, #15, #19, #21, #22, #26, #30, #34, #39, #41]. In striated muscle, SMYD2-methylated HSP90 forms a protective complex with the titin N2A domain, and oxidative glutathionylation of SMYD2 at Cys13 disrupts this complex to destabilize sarcomeres [#7, #8, #10, #24, #25]. SMYD2 activity is amplified by CDK4/6 phosphorylation and limited by STUB1-mediated proteasomal degradation [#29, #33].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established SMYD2 as both a histone methyltransferase and a p53 regulator, defining its dual chromatin and non-histone roles from the outset.\",\n      \"evidence\": \"In vitro methyltransferase assays, Co-IP, and reporter/apoptosis assays showing p53 K370 monomethylation and H3K36me2 with Sin3A association\",\n      \"pmids\": [\"17108971\", \"16805913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide H3K36 targets not mapped\", \"Physiological balance between histone and p53 activity unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed SMYD2 catalytic output is modulated by partner binding, foreshadowing chaperone-coupled regulation of its activity and specificity.\",\n      \"evidence\": \"IP-MS, domain-mapping Co-IP, and in vitro methyltransferase assays mapping HSP90\\u03b1, EBP41L3, and p53 to distinct domains\",\n      \"pmids\": [\"18065756\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which HSP90 shifts specificity to H3K4 unresolved\", \"In vivo relevance of the HSP90 effect not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected SMYD2 methylation to reader-based repression and cell-cycle control by showing RB K860 methylation recruits L3MBTL1.\",\n      \"evidence\": \"In vitro methyltransferase assay, MS site mapping, and L3MBTL1 methyl-binding domain pulldowns\",\n      \"pmids\": [\"20870719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genomic loci of RB-L3MBTL1 effects not defined\", \"Relationship to RB phosphorylation not yet integrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the structural basis for SMYD2 substrate recognition and autoinhibition, explaining how a single enzyme accommodates diverse substrates and how it can be inhibited.\",\n      \"evidence\": \"Crystal structures of SMYD2 with p53 peptide, AZ505, SAH/sinefungin, plus CTD/EDEE mutagenesis with functional assays\",\n      \"pmids\": [\"21782458\", \"21738746\", \"21880715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational dynamics in solution not directly observed\", \"Structural basis for non-p53 substrate selection still limited\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed a cytoplasmic, muscle-specific role linking SMYD2-HSP90 methylation to titin stability and contractile function, distinct from chromatin activity.\",\n      \"evidence\": \"In vitro methyltransferase assays, HSP90 MS site mapping (K209/K615), Co-IP of Smyd2-Hsp90-titin N2A, and zebrafish knockdown muscle/cardiac phenotypes\",\n      \"pmids\": [\"22028380\", \"22241783\", \"23047121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HSP90 methylation is strictly required for titin protection not isolated genetically\", \"Mammalian in vivo confirmation limited\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed SMYD2 methylation can be activating by demonstrating RB K810 methylation enhances RB phosphorylation and E2F-driven proliferation, establishing methylation-phosphorylation crosstalk.\",\n      \"evidence\": \"In vitro/in vivo methylation and phosphorylation assays, LC-MS/MS, E2F reporter, and cell-cycle analysis\",\n      \"pmids\": [\"22787429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which K810 methylation promotes adjacent phosphorylation unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended SMYD2 to nuclear hormone receptor control, showing ER\\u03b1 K266 methylation represses estrogen signaling and competes with p300/CBP acetylation.\",\n      \"evidence\": \"In vitro methyltransferase assay, ChIP, and gene expression analysis in MCF7 cells\",\n      \"pmids\": [\"24101509\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Demethylase reversing K266me not identified\", \"In vivo endocrine relevance not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structurally and biochemically expanded the substrate landscape and chaperone coupling, defining how distinct substrates bind and how HSP90/P23 motifs promote methylation.\",\n      \"evidence\": \"Crystal structure of SMYD2-ER\\u03b1 peptide, HSP90AB1 K531/K574 MS mapping, PARP1 K528 mapping with PAR assay, and reconstituted MPXL-motif/ER\\u03b1 methylation\",\n      \"pmids\": [\"24594358\", \"24880080\", \"24726141\", \"30190324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of chaperone scaffolding in cells unresolved\", \"Functional consequences of HSP90 dimerization-site methylation incompletely defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Cemented the dominant non-histone, cytoplasmic identity of SMYD2 and linked it to oncogenic AKT signaling via PTEN K313 methylation.\",\n      \"evidence\": \"Subcellular fractionation, SILAC proteomics with LLY-507, plus PTEN K313 methylation/mutagenesis and AKT phosphorylation assays\",\n      \"pmids\": [\"25925379\", \"25825497\", \"25583990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The small histone subset SMYD2 targets at specific loci not enumerated\", \"PTEN demethylation/turnover not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Systematically defined the cellular SMYD2 substrate space, demonstrating broad Kme1 substrate diversity beyond canonical targets.\",\n      \"evidence\": \"SILAC Kme1 immunoaffinity proteomics with shRNA and LLY-507 orthogonal validation; identification of BTF3, PDAP1, AHNAK/AHNAK2 sites; plus cell-based IP validation of additional substrates with BAY-598\",\n      \"pmids\": [\"26750096\", \"27163177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of most newly identified sites untested\", \"Site stoichiometry in vivo unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Broadened SMYD2 into receptor kinase, Wnt, inflammatory, and chromatin-compaction pathways, showing context-dependent activating and repressive outcomes.\",\n      \"evidence\": \"In vitro methyltransferase assays and functional readouts for BMPR2/SMAD1-5, ALK/AKT, \\u03b2-catenin K133 nuclear import, STAT3/NF-\\u03baB feedback loops in Pkd1 models, and H4K20me1/L3MBTL1 at the latent HIV-1 promoter\",\n      \"pmids\": [\"28588028\", \"28370702\", \"28915556\", \"28604386\", \"28494238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase-domain methylation sites on receptors not always mapped\", \"Single-lab findings for several pathways\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified redox control of SMYD2 by showing Cys13 glutathionylation disrupts the protective HSP90-titin complex, linking oxidative stress to sarcomere destabilization.\",\n      \"evidence\": \"Clickable glutathione labeling, Co-IP, and MMP-2/calpain proteolysis assays\",\n      \"pmids\": [\"30337525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo demonstration of Cys13 glutathionylation in disease lacking\", \"Reversibility/enzymatic deglutathionylation not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Refined the SMYD2 recognition motif and linked methylation to protein-stability control of oncogenic substrates.\",\n      \"evidence\": \"Peptide-array specificity profiling with substrate validation, and EZH2 K307 methylation/stability assays with LSD1 reversal\",\n      \"pmids\": [\"31612581\", \"31693890\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Motif does not predict in-cell methylation reliably\", \"Generality of methylation-stabilization mechanism unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed SMYD2 in a CDK4/6 feedback circuit and extended its activity to tubulin and ciliogenesis, coupling cell-cycle signaling to cytoskeletal dynamics.\",\n      \"evidence\": \"Kinase and methyltransferase assays, CDK4/6 inhibition, SMYD2 depletion, and cilia assembly assays\",\n      \"pmids\": [\"33127671\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CDK4/6 phosphosite on SMYD2 not mapped\", \"\\u03b1-tubulin methylation site and stoichiometry undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established SMYD2 as a regulator of DNA repair, cell-death, and protein turnover with immune and therapeutic consequences.\",\n      \"evidence\": \"Ku70 site-specific methylation with NHEJ/cGAS-STING readouts, RIPK1 methylation/death-signaling assays, c-Myc methylation/ubiquitination/GLS1 assays, and STUB1-mediated SMYD2 degradation Co-IP/knockdown\",\n      \"pmids\": [\"37315132\", \"35022391\", \"36611819\", \"35939202\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RIPK1 and SMAD-related methylation sites not all mapped\", \"STUB1 ubiquitination of SMYD2 not reconstituted (Low confidence)\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined SMYD2 as a driver of metastasis and therapy resistance through reader-mediated migration and stabilization of hormone receptors, with mechanism-specific in vivo genetic validation.\",\n      \"evidence\": \"BCAR3 K334me1/FMNL reader and mammary-specific KO metastasis assays, KMT2D K1330 methylation/ChIP/PI3K-inhibitor sensitization, PPAR\\u03b3 methylation/nuclear translocation in pulmonary hypertension, and AR methylation/stability in CRPC\",\n      \"pmids\": [\"38296970\", \"38700982\", \"38770649\", \"38243079\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific selectivity among these substrates unresolved\", \"Several mechanisms validated in single labs\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how SMYD2 selects among its many substrates in a given cell type and how its catalytic versus scaffolding functions are partitioned across compartments.\",\n      \"evidence\": \"No timeline discovery resolves substrate prioritization or compartment-specific function\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No quantitative framework for in-cell substrate prioritization\", \"Demethylases for many sites unidentified\", \"Physiological versus oncogenic substrate hierarchy unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 9, 11, 13, 15, 18, 27]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 7, 13, 15, 21, 26, 30]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [1, 17, 35]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 11, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16, 30, 24]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 11, 21]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [10, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 17, 20, 35]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 9, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 19, 22, 23, 30]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [26, 34, 41]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 11, 35]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [13, 31]}\n    ],\n    \"complexes\": [\"Sin3A histone deacetylase complex\", \"Smyd2-HSP90-titin N2A complex\"],\n    \"partners\": [\"HSP90AB1\", \"TP53\", \"RB1\", \"L3MBTL1\", \"ESR1\", \"STUB1\", \"EZH2\", \"BCAR3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}